Effects of Filgrastim in Neonates Having Neonatal Sepsis and Neutropenia
DOI:
https://doi.org/10.70749/ijbr.v3i5.2914Keywords:
Granulocyte colony-stimulating factor, Infant newborn, Neutropenia, SepsisAbstract
Background: Neonatal sepsis with neutropenia is a critical condition that causes increased morbidity and mortality within 28 days of birth. Filgrastim acts by stimulating the bone marrow to increase neutrophils; however, its use in neonates with sepsis is not fully elucidated. Objective: To compare the effect of filgrastim plus conventional therapy versus conventional therapy alone on absolute neutrophil count in neonates having sepsis with neutropenia. Study Design: Randomized controlled trial. Duration and Place of Study: This study was conducted from 1 September 2024 to 1 March 2025 in Department of Pediatrics, Combined Military Hospital Rawalpindi. Methodology: Total 60 neonates aged less than 28 days were included, with 30 in each group. Group A received filgrastim 10 microgram per kilogram per day for 3 days along with conventional therapy, while Group B received conventional therapy only. Absolute neutrophil count was measured at baseline and after 5 days. Data was analyzed using SPSS 23. Results: Baseline absolute neutrophil count was comparable in both groups (913.27 ± 302.00 per millimeter cube versus 871.47 ± 306.32 per millimeter cube). After 5 days, mean absolute neutrophil count was significantly higher in Group A (4872.00 ± 912.94 per millimeter cube) compared to Group B (4052.00 ± 1011.09 per millimeter cube) with p = 0.002. Significant improvement was also seen in neonates aged more than 14 days (p = 0.019), males (p = 0.009), birth weight more than 2.5 kilogram (p = 0.004) and cesarean delivery (p = 0.008). Conclusion: Filgrastim added with conventional therapy significantly improves absolute neutrophil count in neonates having sepsis with neutropenia.
Downloads
References
1. Kariniotaki C, Thomou C, Gkentzi D, Panteris E, Dimitriou G, Hatzidaki E. Neonatal sepsis: a comprehensive review. Antibiotics (Basel). 2024;14(1):6.
https://doi.org/10.3390/antibiotics14010006
2. Chibabhai V, Reddy K, Dramowski A, Yah C, Ballot D, Govender N. Bacterial and fungal pathogens causing neonatal sepsis and associated antimicrobial resistance in South African neonatal units-a systematic review. JAC Antimicrob Resist. 2025;7(6):dlaf214.
https://doi.org/10.1093/jacamr/dlaf214
3. Celik IH, Hanna M, Canpolat FE, Mohan Pammi. Diagnosis of neonatal sepsis: the past, present and future. Pediatr Res. 2022;91(2):337-350.
https://doi.org/10.1038/s41390-021-01696-z
4. Sullivan E, Schulte R, Speaker SL, Sabharwal P, Wang M, Rothberg MB. Relationship between white blood cell count and bacteremia using interval likelihood ratios in hospitalized patients. J Gen Intern Med. 2025;40(3):532-537.
https://doi.org/10.1007/s11606-024-09119-5
5. Fakih H, Hussein H, Fakih F. A case of severe neonatal neutropenia secondary to late-onset sepsis from E. coli omphalitis. Cureus. 2026;18(1):e101601.
https://doi.org/10.7759/cureus.101601
6. Lawrence SM. Should granulocyte transfusion therapy for septic neutropenic neonates be resurrected? Semin Fetal Neonatal Med. 2025;30(1):101616.
https://doi.org/10.1016/j.siny.2025.101616
7. Attia Hussein Mahmoud H, Parekh R, Dhandibhotla S, Sai T, Pradhan A, Alugula S, et al. Insight into neonatal sepsis: an overview. Cureus. 2023;15(9):e45530.
https://doi.org/10.7759/cureus.45530
8. Iijima S. Exchange transfusion in neonatal sepsis: a narrative literature review of pros and cons. J Clin Med. 2022;11(5):1240.
https://doi.org/10.3390/jcm11051240
9. Berends C, Maggen C, Lok CAR, van Gerwen M, Boere IA, Wolters VERA, et al. Maternal and neonatal outcome after the use of G-CSF for cancer treatment during pregnancy. Cancers (Basel). 2021;13(6):1214.
https://doi.org/10.3390/cancers13061214
10. Li L, Yang B, Gao XY, Ren Y, Su M, Yang CY, et al. Risk factors for neutropenia of late newborns. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(4):375-380.
https://doi.org/10.7499/j.issn.1008-8830.2012026
11. Beudeker CR, Vijlbrief DC, van Montfrans JM, Rooijakkers SHM, van der Flier M. Neonatal sepsis and transient immunodeficiency: potential for novel immunoglobulin therapies? Front Immunol. 2022; 13:1016877.
https://doi.org/10.3389/fimmu.2022.1016877
12. Bottari G, Taccone FS, Corrias A, Irrera M, Currao P, Salvagno M, et al. Immunomodulation in pediatric sepsis: a narrative review. J Clin Med. 2025;14(9):2983.
https://doi.org/10.3390/jcm14092983
13. Chaudhuri J, Mitra S, Mukhopadhyay D, Chakraborty S, Chatterjee S. Granulocyte colony-stimulating factor for preterms with sepsis and neutropenia: a randomized controlled trial. J Clin Neonatol. 2012;1(4):202-206.
https://doi.org/10.4103/2249-4847.105993
14. Gupta P, Sethi RS, Chaurasia OS, Sethi A. Role of granulocyte colony stimulating factor (G-CSF) in neonatal sepsis with neutropenia. People's J Sci Res. 2016;9(2):7-13.
15. Aktas D, Demirel B, Gürsoy T, Ovalı F. A randomized case-controlled study of recombinant human granulocyte colony stimulating factor for the treatment of sepsis in preterm neutropenic infants. Pediatr Neonatol. 2015;56(3):171-175.
https://doi.org/10.1016/j.pedneo.2014.06.007
16. Verzosa GS, Yu MMC, Senen KA, Quilendrino MI. Granulocyte colony stimulating factor in improving outcomes of neonatal sepsis: a meta-analysis. Pediatr Infect Dis Soc Philipp J. 2018;19(1):40-53.
https://doi.org/10.56964/pidspj20181901007
17. Wolach B, Gavrieli R, Pomeranz A, Meranz D, Bar-El S. Effect of granulocyte and granulocyte macrophage colony stimulating factors (G-CSF and GM-CSF) on neonatal neutrophil functions. Pediatr Res. 2000;48(3):369-373.
https://doi.org/10.1203/00006450-200009000-00016
18. Reddy KK, Rao SK, Saroj AK, Srivastava C, Singh TB, Palandurkar KM. Efficacy of the granulocyte colony-stimulating factor in sepsis-associated immunosuppression: an open-label randomized controlled trial. Cureus. 2026;18(2):e104055. https://doi.org/10.7759/cureus.104055
19. Golpayegani MR, Faranoush P, Rasouli MH, Foroughi-Gilvaee M, Sadighnia N, Zandi A, et al. Comparative study on the effects of filgrastim and pegfilgrastim in the treatment of fever and neutropenia in patients with leukemia in the west of Iran. Iran J Ped Hematol Oncol. 2022;12(2):76-85.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
